[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586110":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":41,"responsibleParty":135,"collaborators":30,"id":137,"slug":138,"hasResults":139,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":30,"eligibilityCriteria":143,"healthyVolunteers":139,"sex":144,"minAge":145,"maxAge":30,"enrollmentInfo":146,"targetDuration":30,"studyType":149,"phases":150,"briefSummary":152,"conditions":153,"keywords":155,"overallStatus":44,"whyStopped":30,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":168},{"fullName":5,"class":6},"Neurocrine Biosciences","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"NBI-1065845","EXPERIMENTAL","NBI-1065845 administered orally once a day.",[13],"Drug: NBI-1065845",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Placebo identical in appearance to NBI-1065845 will be administered orally once a day.",[19],"Drug: Placebo",[21,27],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","NBI-1065845 tablets",[9],[26],"TAK-653",{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":30},"Matching placebo tablets",[15],null,[32],{"name":33,"affiliation":5,"role":34},"Clinical Development Lead","STUDY_DIRECTOR",[36],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},"Neurocrine Medical Information Call Center","CONTACT","1-877-641-3461","medinfo@neurocrine.com",[42,56,65,73,82,90,99,108,117,126],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":30},"Neurocrine Clinical Site","RECRUITING","Huntsville","Alabama","35801","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-86.58594,34.7304,{"lat":54,"lon":53},{"facility":43,"status":44,"city":57,"state":58,"zip":59,"country":48,"countryCode":49,"cosmosGeoPoint":60,"geoPoint":64,"contacts":30},"Glendale","California","91206",{"type":51,"coordinates":61},[62,63],-118.25508,34.14251,{"lat":63,"lon":62},{"facility":43,"status":44,"city":66,"state":58,"zip":67,"country":48,"countryCode":49,"cosmosGeoPoint":68,"geoPoint":72,"contacts":30},"Irvine","92614",{"type":51,"coordinates":69},[70,71],-117.82311,33.66946,{"lat":71,"lon":70},{"facility":43,"status":44,"city":74,"state":75,"zip":76,"country":48,"countryCode":49,"cosmosGeoPoint":77,"geoPoint":81,"contacts":30},"Miami","Florida","33174",{"type":51,"coordinates":78},[79,80],-80.19366,25.77427,{"lat":80,"lon":79},{"facility":43,"status":44,"city":83,"state":75,"zip":84,"country":48,"countryCode":49,"cosmosGeoPoint":85,"geoPoint":89,"contacts":30},"Tampa","33607",{"type":51,"coordinates":86},[87,88],-82.45843,27.94752,{"lat":88,"lon":87},{"facility":43,"status":44,"city":91,"state":92,"zip":93,"country":48,"countryCode":49,"cosmosGeoPoint":94,"geoPoint":98,"contacts":30},"Atlanta","Georgia","30318",{"type":51,"coordinates":95},[96,97],-84.38798,33.749,{"lat":97,"lon":96},{"facility":43,"status":44,"city":100,"state":101,"zip":102,"country":48,"countryCode":49,"cosmosGeoPoint":103,"geoPoint":107,"contacts":30},"Boston","Massachusetts","02131",{"type":51,"coordinates":104},[105,106],-71.05977,42.35843,{"lat":106,"lon":105},{"facility":43,"status":44,"city":109,"state":110,"zip":111,"country":48,"countryCode":49,"cosmosGeoPoint":112,"geoPoint":116,"contacts":30},"Saint Charles","Missouri","63304",{"type":51,"coordinates":113},[114,115],-90.48123,38.78394,{"lat":115,"lon":114},{"facility":43,"status":44,"city":118,"state":119,"zip":120,"country":48,"countryCode":49,"cosmosGeoPoint":121,"geoPoint":125,"contacts":30},"The Bronx","New York","10461",{"type":51,"coordinates":122},[123,124],-73.86641,40.84985,{"lat":124,"lon":123},{"facility":43,"status":44,"city":127,"state":128,"zip":129,"country":48,"countryCode":49,"cosmosGeoPoint":130,"geoPoint":134,"contacts":30},"Mason","Ohio","45040",{"type":51,"coordinates":131},[132,133],-84.30994,39.36006,{"lat":133,"lon":132},{"type":136,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100586110","phase-3-nbi-1065845-mdd3025-study-to-assess-the-efficacy-and-safety-of-nbi-1065845-as-an-adjunctive-treatment-in-participants-with-major-depressive-disorder-mdd-100586110",false,"NCT06911112","NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)","A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 as Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)","Key Inclusion Criteria:\n\n* Participant has a primary diagnosis of recurrent MDD (moderate or severe) or persistent depressive disorder.\n* Participant has had an inadequate response to oral antidepressant treatments in the current episode of depression.\n* Participant must have been taking oral antidepressants for at least 8 weeks and is willing to continue the same oral antidepressants at the same dose and frequency of administration throughout participation in the study.\n* Total Hamilton Depression Rating Scale-17 Item (HAM-D17) score ≥22 at screening and at study baseline (Day 1).\n* Willing and able to comply with all study procedures and restrictions in the opinion of the investigator.\n\nKey Exclusion Criteria:\n\n* A current or prior psychiatric disorder diagnosis in the last 1 year that was the primary focus of treatment other than MDD.\n* Are considered by the investigator to be at imminent risk of suicide or injury to self or others.\n* Participants depressive symptoms have previously demonstrated nonresponse to electroconvulsive therapy (ECT) in the current major depressive episode.","ALL","18 Years",{"count":147,"type":148},200,"ESTIMATED","INTERVENTIONAL",[151],"PHASE3","The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.",[154],"Major Depressive Disorder",[156,157,154,9,26,158],"MDD","Depression","MADRS","2025-11-26",{"date":161,"type":162},"2025-12-01","ACTUAL",{"date":164,"type":162},"2025-03-31",{"date":166,"type":148},"2027-07",{"name":5,"class":6},10]